SARS-CoV-2 causes clinical symptoms by killing cells in the lung and by causing inflammation that further exacerbates clinical symptoms. “In addition to anti-viral therapy, a comprehensive strategy in treating COVID-19 patients should include a non-antiviral approach targeting the tissue injury-induced inflammation”, said Dr. Pan Zheng, Chief Medical Officer and co-founder of OncoImmune. CD24Fc will be tested in combination with the best available therapy. Patients receiving other experimental therapies are welcome to participate in the trial.
“CD24Fc is a first-in-class biologic that fortifies an innate immune checkpoint against excessive inflammation caused by tissue-injuries. We are very excited to launch a global effort to test the clinical efficacy of CD24Fc in speeding up recovery of hospitalized COVID-19 patients”, said Dr. Yang Liu, CEO and co-founder.